ONC vs REGN
BeOne Medicines AG and Regeneron Pharmaceuticals, both Healthcare
Regeneron Pharmaceuticals is the larger company at $98B against $46B. Over the past year REGN returned +45% against +23% for ONC.
| Figure | ONC | Both figures drawn to one scale | REGN |
|---|---|---|---|
| Last close | $404 | $945 | |
| Market cap | $46B | $98B | |
| Trailing P/Eshare price over earnings per share | n/a | 20.9 | |
| Revenue growthlast twelve months on the year before | n/a | +19% | |
| Operating margin | n/a | 29% | |
| Net margin | n/a | 29% | |
| Free cash flow yield | n/a | 3.9% | |
| Net cashcash minus all debt | n/a | $7.3B | |
| Insiders, 12 monthsopen-market Form 4 trades | sold $392M net | sold $58M net | |
| 1-year return | +23% | +45% | |
| 5-year return | +8.0% | +46% |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher number in each row, nothing more.
BeOne Medicines AG
Regeneron Pharmaceuticals
Revenue of $5.1B in the quarter to Sep 30, 2026, net income $1.9B. Its largest reported line is Share Of Profit (Losses), 50% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.